Key Takeaways
- • Jardine Matheson Holdings acquired Australia's I-MED Radiology Network for A$3.4 billion (US$2.4 billion), acquiring 100% ownership from private equity firm Permira and other shareholders, with the deal expected to close later in 2026.
- • I-MED operates 215 diagnostic imaging clinics across Australia and New Zealand, performing over 7 million procedures annually and holding a minority stake in Harrison.ai, a radiology artificial intelligence solutions developer.
- • The acquisition aligns with Jardine Matheson's strategic expansion under newly appointed CEO Lincoln Pan, following the company's January 2026 acquisition of Mandarin Oriental International (valued at US$4.2 billion) and reflects management's focus on controlling market-leading healthcare diagnostics assets.
- • Jardine Matheson financed the transaction through balance sheet cash and debt while maintaining 2026 earnings guidance and dividend outlook; the company's stock gained 2.3% on May 25 following the announcement and has surged 56% over the prior 12 months, valuing the firm at US$21.1 billion.
Summary
Jardine Matheson Holdings, the Hong Kong-Singapore-listed conglomerate, announced on Monday, May 26, 2026, the acquisition of I-MED Radiology Network, Australia's leading diagnostic imaging provider, in a deal valued at A$3.4 billion (approximately US$2.4 billion). The transaction represents a full acquisition of 100% ownership from private equity firm Permira, which has backed the radiology network alongside other shareholders. The deal is expected to close later in 2026.
I-MED operates a substantial platform spanning 215 diagnostic imaging clinics across Australia and New Zealand, with annual procedure volume exceeding 7 million cases. The acquisition also transfers to Jardine Matheson a minority stake in Harrison.ai, a specialized developer of radiology artificial intelligence solutions, positioning the combined entity at the intersection of conventional diagnostic imaging and emerging AI-driven diagnostic capabilities.
The transaction reflects Jardine Matheson's accelerated capital allocation strategy under newly appointed CEO Lincoln Pan, who assumed leadership in 2025 following three decades under previous management. The company has demonstrated aggressive expansion momentum, having completed its January 2026 acquisition of Mandarin Oriental International for US$4.2 billion. The I-MED acquisition underscores management's stated priority to acquire and control market-leading healthcare diagnostics assets as part of its broader portfolio strategy.
Jardine Matheson financed the acquisition through a combination of balance sheet cash and debt facilities. Management has explicitly maintained both 2026 earnings guidance and dividend outlook, indicating confidence in the transaction's accretive profile and capital structure sustainability. Market reaction was positive, with Jardine Matheson shares gaining 2.3% in Singapore trading on May 25, the day before the formal announcement. The stock has appreciated 56% over the preceding 12-month period, valuing the company at US$21.1 billion as of the transaction announcement.
I-MED operates a substantial platform spanning 215 diagnostic imaging clinics across Australia and New Zealand, with annual procedure volume exceeding 7 million cases. The acquisition also transfers to Jardine Matheson a minority stake in Harrison.ai, a specialized developer of radiology artificial intelligence solutions, positioning the combined entity at the intersection of conventional diagnostic imaging and emerging AI-driven diagnostic capabilities.
The transaction reflects Jardine Matheson's accelerated capital allocation strategy under newly appointed CEO Lincoln Pan, who assumed leadership in 2025 following three decades under previous management. The company has demonstrated aggressive expansion momentum, having completed its January 2026 acquisition of Mandarin Oriental International for US$4.2 billion. The I-MED acquisition underscores management's stated priority to acquire and control market-leading healthcare diagnostics assets as part of its broader portfolio strategy.
Jardine Matheson financed the acquisition through a combination of balance sheet cash and debt facilities. Management has explicitly maintained both 2026 earnings guidance and dividend outlook, indicating confidence in the transaction's accretive profile and capital structure sustainability. Market reaction was positive, with Jardine Matheson shares gaining 2.3% in Singapore trading on May 25, the day before the formal announcement. The stock has appreciated 56% over the preceding 12-month period, valuing the company at US$21.1 billion as of the transaction announcement.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.